WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--In data presented today at the American Heart Association’s Scientific Sessions 2006 in Chicago, coadministration of MK-0524, an investigational DP1-receptor antagonist, with extended-release niacin (ERN) significantly reduced flushing in patients with dyslipidemia compared to those patients who took ERN alone. Flushing, characterized by redness of the skin with warming or burning on the face and neck caused by the dilation of blood vessels near the skin, is a common niacin-induced side effect that can cause discomfort to patients and is a significant factor leading to discontinuation of niacin therapy.
